BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT)
(“BriaCell” or the “Company”), a clinical-stage biotechnology
company that develops novel immunotherapies to transform cancer
care, today announces that it will host a virtual KOL event on
Bria-IMT™ potential in advanced metastatic breast cancer on
Thursday, October 26, 2023 at 10:00am ET. To register for the
event, please click here.
The event will feature KOLs Adam M. Brufsky, MD,
PhD, FACP (University of Pittsburgh School of Medicine) and Saranya
Chumsri, MD (Mayo Clinic) who will discuss the unmet medical need
and current treatment landscape for patients suffering from
advanced metastatic breast cancer, along with the combination study
of Bria-IMT™ with immune check point inhibitor.
Dr. William V. Williams, BriaCell’s President
& CEO, and Dr. Giuseppe Del Priore, BriaCell’s Chief Medical
Officer, will provide a pipeline overview and highlight the next
steps for the Phase 3 study, and will be available to answer
questions.
The event’s agenda is summarized below:
BriaCell Virtual KOL Event Agenda –
October 26, 2023
Dr. William Williams (CEO) – Introduction and
opening remarksDr. Giuseppe Del Priore (CMO) – Event agenda and KOL
introductionsDr. Adam Brufsky (KOL) – Review all metastatic breast
cancer and current treatment landscapeDr. Saranya Chumsri (KOL) –
Bria-IMT™ Clinical data to date & Phase 3 clinical study
details Q&A Drs. Del Priore and Williams – Summary and next
steps
About Adam M. Brufsky, MD,
PhDDr. Brufsky is Professor of Medicine at the University
of Pittsburgh School of Medicine. He serves as Co-Director,
Comprehensive Breast Cancer Center and Medical Director, Women’s
Cancer Center at the UPMC Magee Women’s Hospital, Pittsburgh, PA.
Dr. Brufsky received an AB in Chemistry (Cum Laude) from Dartmouth
College in Hanover, New Hampshire. He earned his MD and his PhD in
Developmental Biology at the University of Connecticut School of
Medicine in Farmington, CT. He was an Intern and Resident in
Internal Medicine at Brigham and Women’s Hospital, Harvard Medical
School, Boston, MA. He then completed a Fellowship in Medical
Oncology and Bone Marrow Transplantation and the Dana-Farber Cancer
Institute, Harvard Medical School, Boston, MA, where his
appointments included Associate Physician and Instructor in
Medicine at Dana Farber Cancer Institute and Harvard Medical School
in Boston, MA. Dr. Brufsky is board certified in Internal Medicine
and Medical Oncology by the American Board of Internal Medicine. He
is an active member of the American Society of Clinical Oncology
and the American Association for Cancer Research. He has authored
or co-authored more than 300 abstracts and research articles in
leading journals, including the New England Journal of Medicine,
Journal of Clinical Investigation, Journal of Clinical Oncology,
and Lancet Oncology. Dr. Brufsky is a Principal Investigator on a
number of research grants funded by the National Institutes of
Health, Susan G. Komen Foundation, and US Army Breast Cancer
Research Program.
About Saranya Chumsri, MDDr.
Chumsri is a breast cancer oncologist and Professor of Oncology at
Mayo Clinic, FL. Through clinical trials, she has developed
expertise in immunotherapy, cancer vaccines, triple-negative breast
cancer, endocrine-resistant breast cancer, and related
combinational studies. She currently serves as the Mayo Clinic
enterprise research chair for the Breast Disease Group. Moreover,
Dr. Chumsri also serves on multiple international steering
committees, including (Neo) ALTTO steering committee, ACCRU
Consortium Breast Cancer Committee, and the Alliance for Clinical
Trials in Oncology Immuno-Oncology Committee. She is
clinician-scientist reviewer for the Breast Cancer Research Program
(BCRP) for the Department of Defense Congressionally Directed
Medical Research Programs (CDMRP), and leads the Experimental
Trials for Precision Medicine at the Jacoby Center for Breast
Health committee at Mayo Clinic, FL. Dr. Chumsri has received
funding awards from the Department of Defense, National Cancer
Institute, Foundations, and pharmaceutical companies to conduct
novel clinical trials in immuno-oncology and cancer vaccines for
both the treatment and prevention of breast cancer. She received
the prestigious Career Catalyst Research Grant from Susan G. Komen
for the Cure and the Outstanding Research Award from the Department
of Medicine at Mayo Clinic, FL. Dr. Chumsri completed her medical
degree at Chulalongkorn University in Bangkok, Thailand, and her
residencies in internal medicine at the Albert Einstein Medical
Center and in Hematology and Oncology at the University of
Maryland. She has authored over 63 publications.
About BriaCell Therapeutics
Corp.
BriaCell is a clinical-stage biotechnology
company that develops novel immunotherapies to transform cancer
care. More information is available at https://briacell.com/.
Safe Harbor
This press release contains “forward-looking
statements” that are subject to substantial risks and
uncertainties. All statements, other than statements of historical
fact, contained in this press release are forward-looking
statements. Forward-looking statements contained in this press
release may be identified by the use of words such as “anticipate,”
“believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,”
“seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,”
“target,” “aim,” “should,” “will,” “would,” or the negative of
these words or other similar expressions, although not all
forward-looking statements contain these words. Forward-looking
statements, including those relating to the Company hosting the
virtual KOL event described herein and the potential topics
discussed at such event, are based on BriaCell’s current
expectations and are subject to inherent uncertainties, risks, and
assumptions that are difficult to predict. Further, certain
forward-looking statements are based on assumptions as to future
events that may not prove to be accurate. These and other risks and
uncertainties are described more fully under the heading “Risks and
Uncertainties” in the Company's most recent Management’s Discussion
and Analysis, under the heading "Risk Factors" in the Company's
most recent Annual Information Form, and under “Risks and
Uncertainties” in the Company's other filings with the Canadian
securities regulatory authorities and the U.S. Securities and
Exchange Commission, all of which are available under the Company's
profiles on SEDAR at www.sedar.com and on EDGAR at
www.sec.gov. Forward-looking statements contained
in this announcement are made as of this date, and BriaCell
Therapeutics Corp. undertakes no duty to update such information
except as required under applicable law.
Neither the Toronto Stock Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the Toronto Stock Exchange) accepts responsibility for
the adequacy or accuracy of this release.
Contact Information
Company Contact:William V.
Williams, MDPresident &
CEO1-888-485-6340info@briacell.com
Media Relations:Jules
AbrahamDirector of Public RelationsCORE
IR917-885-7378julesa@coreir.com
Investor Relations Contact:CORE
IRinvestors@briacell.com
BriaCell Therapeutics (NASDAQ:BCTXW)
Historical Stock Chart
From Jul 2024 to Aug 2024
BriaCell Therapeutics (NASDAQ:BCTXW)
Historical Stock Chart
From Aug 2023 to Aug 2024